E-ISSN 2231-3206 | ISSN 2320-4672
 

Review Article 


A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar.

Abstract
One of the most frequent problems in medical care is the management of patient presenting with chronic pain. Neuropathic pain is related to the injury or disorders affecting peripheral and central nervous systems and is resistant to over-the-counter analgesics and conventional treatment methods. The estimated prevalence for patients presenting classical symptoms of neuropathic pain is eventually reported to be 6%–8%. Several mechanisms have been considered and proposed for this disorder. The involvement of small and large sensory fibers as well as motor fibers is a reason for the presence of neuropathic pain. In addition to the lifestyle modification, a number of different therapeutic approaches and treatment protocols have been applied to control the neuropathic pain. However, management is still unsatisfactory. Comorbidities such as depression, anxiety, and sleep disorders are associated with this disorder and should be previously considered and eliminated. Analgesics, tricyclic antidepressants, anticonvulsant, serotonin– norepinephrine reuptake inhibitors, and local anesthetic agent as well as opioid analgesics and herbal medicaments such as capsaicin are known treatment lines for the management of neuropathic pain. Regarding the unsuccessfulness of single therapy, poly-pharmacy or combination therapy of two or more agents with synergistic mechanisms and different modes of action seems necessary.

Key words: Neuropathy, Neuropathic Pain, Chronic Pain


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Mohammad M Zarshenas
Articles by Mahmoodreza Moein
Articles by Soliman Mohammadi Samani
Articles by Peyman Petramfar
on Google
on Google Scholar


REFERENCES
1. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19. [DOI via Crossref]   
2. Smith HS, Sang CN. The evolving nature of neuropathic pain: individualizing treatment. Eur J Pain. 2002;6:13-18. [DOI via Crossref]   
3. Tanelian DL, Cousins MJ. Combined neurogenic and nociceptive pain in a patient with Pancoast tumor managed by epidural hydromorphone and oral carbamazepine. Pain. 1989;36(1):85-8. [DOI via Crossref]   
4. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;429(1-3):1-11. [DOI via Crossref]   
5. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther. 1988;43(4):363-71. [DOI via Crossref]    [Pubmed]   
6. Galluzzi KE. Management of neuropathic pain. J Am Osteopath Assoc. 2005;105(4):12-19.
7. Gilron I, Watson CPN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. Can Med Assoc J. 2006; 175(3):265-75. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
8. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16(3):191-8. [DOI via Crossref]    [Pubmed]   
9. Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neuro. 2006;2(2):95-106. [DOI via Crossref]    [Pubmed]   
10. Baron R. Neuropathic pain: a clinical perspective. In: Canning BJ, Spina D (eds.), Sensory Nerves. Berlin Heidelberg: Springer, 2009. pp. 3-30. [DOI via Crossref]    [Pubmed]   
11. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 2000;16(2):12-20. [DOI via Crossref]   
12. Bennett GJ. The role of the sympathetic nervous system in painful peripheral neuropathy. Pain. 1991;45(3):221-3. [DOI via Crossref]   
13. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353(9168):1959-64. [DOI via Crossref]   
14. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 2003;25(5):4-11. [DOI via Crossref]   
15. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83(3):389-400. [DOI via Crossref]   
16. Truini A, Cruccu G. Pathophysiological mechanisms of neuropathic pain. Neurol Sci. 2006;27(2):179-82. [DOI via Crossref]    [Pubmed]   
17. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson J, et al. Harrison’s Principles of Internal Medicine, 17 edn., New York: McGraw-Hill, 2008.
18. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol. 1998;44(1):47-59. [DOI via Crossref]    [Pubmed]   
19. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006;29(4):883-7. [DOI via Crossref]    [Pubmed]   
20. Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002;26(2):173-88. [DOI via Crossref]    [Pubmed]   
21. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 1998;51(3):695-702. [DOI via Crossref]    [Pubmed]   
22. Schestatsky P, Nascimento OJ. What do general neurologists need to know about neuropathic pain? Arq Neuropsiquiatr. 2009;67(3):741-9. [DOI via Crossref]    [Pubmed]   
23. Bennett MI. Theories, history and current taxonomy. Neuropathic Pain. London: Oxford University Press, 2006.
24. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain— consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21. [Pubmed]    [PMC Free Fulltext]   
25. Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain. 2009;141(1):19-24. [DOI via Crossref]    [Pubmed]   
26. Wolfe GI, Barohn R. Painful peripheral neuropathy. Curr Treat Options Neurol. 2002;4:177-88. [DOI via Crossref]   
27. Huizinga MM, Peltier A. Painful diabetic neuropathy: a managementcentered review. Clin Diabetes. 2007;25(1):6-15. [DOI via Crossref]   
28. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11):1524-34. [DOI via Crossref]    [Pubmed]   
29. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-51. [DOI via Crossref]    [Pubmed]   
30. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289-305. [DOI via Crossref]    [Pubmed]   
31. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):164. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
32. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350-4. [DOI via Crossref]    [Pubmed]   
33. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007;130(1-2):66-75. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
34. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998;51(6):1682-8. [DOI via Crossref]    [Pubmed]   
35. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori. 2002;88(3):239-42. [Pubmed]   
36. Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM, Loeser JD. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain. 2002;96 (3):365-73. [DOI via Crossref]   
37. Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60(17):4-8. [Pubmed]   
38. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250-6. [DOI via Crossref]    [Pubmed]   
39. Williams GO. Management of depression in the elderly. Prim Care. 1989;16(2):451-74. [Pubmed]   
40. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Jr., Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279 (4):287-91. [DOI via Crossref]    [Pubmed]   
41. Taylor CP. The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003. CNS Drug Rev. 2004; 10(2):183-8. [DOI via Crossref]    [Pubmed]   
42. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-6. [DOI via Crossref]    [Pubmed]   
43. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115(3):254-63. [DOI via Crossref]    [Pubmed]   
44. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67(10): 1792-800. [DOI via Crossref]    [Pubmed]   
45. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9(11):1006-17. [DOI via Crossref]    [Pubmed]   
46. Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48(6):1714-17. [DOI via Crossref]    [Pubmed]   
47. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505-09. [DOI via Crossref]    [Pubmed]   
48. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-18. [DOI via Crossref]    [Pubmed]   
49. Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346-56. [DOI via Crossref]    [Pubmed]   
50. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60(8):1284-9. [DOI via Crossref]    [Pubmed]   
51. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36(2):236-40. [DOI via Crossref]    [Pubmed]   
52. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37(2):246-53. [DOI via Crossref]    [Pubmed]   
53. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3):3-14. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
54. Wu CL, Agarwal S, Tella PK, Klick B, Clark MR, Haythornthwaite JA, et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology. 2008;109(2):289-96. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
55. Jackson KC, 2nd. Pharmacotherapy for neuropathic pain. Pain Pract. 2006;6(1):27-33. [DOI via Crossref]    [Pubmed]   
56. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101(6):1738-49. [DOI via Crossref]    [Pubmed]   
57. Stacey BR. Management of peripheral neuropathic pain. Am J Phys Med Rehabil. 2005;84(3):4-16.
58. Namaka M, Leong C, Grossberndt A, Klowak M, Turcotte D, Esfahani F, et al. A treatment algorithm for neuropathic pain: an update. Consult Pharm. 2009;24(12):885-902. [DOI via Crossref]    [Pubmed]   
59. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9): 1815-23. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
60. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘‘enriched enrollment’’ design. Pain. 1995;60(3): 267-74. [DOI via Crossref]   
61. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults Cochrane Database Syst Rev 2009(4) CD007393. [DOI via Crossref]   
62. Wagner T, Roth-Daniek A, Sell A, England J, Kern K-U. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from ‘‘real-world’’ clinical experience. Pain Manag. 2012; 2(3):239-50. [DOI via Crossref]    [Pubmed]   
63. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328(7446):991. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
64. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816-24. [DOI via Crossref]    [Pubmed]   
65. Jancso G, Kiraly E, Jancso-Gabor A. Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature. 1977;270(5639):741-3. [DOI via Crossref]    [Pubmed]   
66. Minami T, Bakoshi S, Nakano H, Mine O, Muratani T, Mori H, et al. The effects of capsaicin cream on prostaglandin-induced allodynia. Anesth Analg. 2001;93(2):419-23. [Pubmed]   
67. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012;9:CD010111. [DOI via Crossref]   
68. Lynch ME, Clark AJ, Sawynok J. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, doubleblind, placebo-controlled trial. Anesthesiology. 2005;103:140-6. [DOI via Crossref]    [Pubmed]   
69. Lockhart E. Topical analgesics: topical combination of amitriptyline and ketamine for post herpetic neuralgia. J Pain. 2004;5:82. [DOI via Crossref]   
70. McCleane GJ. Topical doxepin hydrochloride reduces neuropathic pain: a randomized, double-blind, placebo controlled study. Pain Clin. 2000;12:47-50. [DOI via Crossref]   

How to Cite this Article
Pubmed Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. Natl J Physiol Pharm Pharmacol. 2015; 5(3): 160-165. doi:10.5455/njppp.2015.5.2812201418


Web Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. https://www.njppp.com/?mno=176260 [Access: June 01, 2022]. doi:10.5455/njppp.2015.5.2812201418


AMA (American Medical Association) Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. Natl J Physiol Pharm Pharmacol. 2015; 5(3): 160-165. doi:10.5455/njppp.2015.5.2812201418



Vancouver/ICMJE Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. Natl J Physiol Pharm Pharmacol. (2015), [cited June 01, 2022]; 5(3): 160-165. doi:10.5455/njppp.2015.5.2812201418



Harvard Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar (2015) A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. Natl J Physiol Pharm Pharmacol, 5 (3), 160-165. doi:10.5455/njppp.2015.5.2812201418



Turabian Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. 2015. A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. National Journal of Physiology, Pharmacy and Pharmacology, 5 (3), 160-165. doi:10.5455/njppp.2015.5.2812201418



Chicago Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. "A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain." National Journal of Physiology, Pharmacy and Pharmacology 5 (2015), 160-165. doi:10.5455/njppp.2015.5.2812201418



MLA (The Modern Language Association) Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar. "A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain." National Journal of Physiology, Pharmacy and Pharmacology 5.3 (2015), 160-165. Print. doi:10.5455/njppp.2015.5.2812201418



APA (American Psychological Association) Style

Mohammad M Zarshenas, Mahmoodreza Moein, Soliman Mohammadi Samani, Peyman Petramfar (2015) A glimpse into the pathophysiology, mechanisms, and management of neuropathic pain. National Journal of Physiology, Pharmacy and Pharmacology, 5 (3), 160-165. doi:10.5455/njppp.2015.5.2812201418